Return to Listing

5 result(s) for Non-Small Cell

PI Name Protocol # Title
Jeremy Cetnar IRB00011046 S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Khaled Tolba IRB00011462 A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) plus nab-Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Matthew Taylor IRB00011804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Jeremy Cetnar IRB00011851 A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN + NAB-PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER
Khaled Tolba IRB00012012 A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (ANTI−PD-L1 ANTIBODY) Compared With Best Supportive Care Following adjuvant Cisplatin-Based Chemotherapy In PD-L1−Selected Patients With Completely Resected STAGE IB−IIIA
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080